Senolytics and Senomorphics: Breakthrough Longevity Drugs for Healthy Aging

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Senolytics and senomorphics are emerging longevity drugs that target aging cells to promote healthy aging and reduce age-related diseases. Consult a healthcare provider before use.

# Senolytics and Senomorphics: Breakthrough Longevity Drugs for Healthy Aging

Aging is a natural process characterized by a decline in physiological functions and an increased risk of chronic diseases. Recent advances in biogerontology have identified cellular senescence as a key driver of aging and age-related diseases. This has led to the development of senolytics and senomorphics—two promising classes of drugs aimed at promoting healthy aging by targeting senescent cells. This article explores the science behind these breakthrough longevity drugs, their mechanisms, evidence from research, and practical considerations.

---

Understanding Cellular Senescence and Aging

What Are Senescent Cells?

Cellular senescence is a state in which cells permanently stop dividing but do not die. These senescent cells accumulate in tissues over time, secreting inflammatory cytokines, growth factors, and proteases—a phenomenon known as the senescence-associated secretory phenotype (SASP). The SASP contributes to chronic inflammation, tissue dysfunction, and the progression of many age-related conditions such as osteoarthritis, cardiovascular disease, and neurodegeneration.

Why Target Senescent Cells?

While senescence plays a beneficial role in wound healing and tumor suppression, the buildup of senescent cells over time is detrimental. Removing or modulating these cells has been proposed as a strategy to delay or reverse aspects of aging and improve healthspan—the period of life spent in good health.

---

Senolytics: Drugs That Selectively Eliminate Senescent Cells

Mechanism of Action

Senolytics are compounds that selectively induce death of senescent cells by exploiting their unique survival pathways. Senescent cells resist apoptosis (programmed cell death) through upregulation of anti-apoptotic pathways. Senolytics inhibit these pathways, allowing the immune system to clear senescent cells and reduce SASP-driven inflammation.

Examples of Senolytics

  • Dasatinib and Quercetin (D+Q): A combination of a cancer drug (dasatinib) and a natural flavonoid (quercetin) has been widely studied. This combo targets senescent cells in various tissues.
  • Fisetin: A plant polyphenol with senolytic properties shown to reduce senescent cell burden in animal studies.
  • Navitoclax: A BCL-2 family inhibitor, though with concerns about side effects such as thrombocytopenia.

    • Evidence from Research

  • In a landmark study, D+Q improved physical function and reduced senescent cell markers in patients with idiopathic pulmonary fibrosis (IPF) (Justice et al., 2019).
  • Fisetin extended lifespan and reduced frailty in aged mice, demonstrating senolytic activity (Yousefzadeh et al., 2018).
  • Animal models show senolytic treatment improves cardiac function, kidney health, and cognitive performance.

    • ---

    Senomorphics: Drugs That Modulate Senescent Cell Behavior

    Mechanism of Action

    Unlike senolytics, senomorphics do not kill senescent cells but suppress their harmful SASP secretion. By modulating the inflammatory phenotype, senomorphics reduce tissue damage and inflammation associated with aging.

    Examples of Senomorphics

  • Rapamycin (Sirolimus): An mTOR inhibitor that suppresses SASP and promotes longevity in multiple species.
  • Metformin: A widely used diabetes drug that exhibits senomorphic and other geroprotective effects.
  • JAK inhibitors: Reduce SASP factors by blocking inflammatory signaling pathways.

    • Evidence from Research

  • Rapamycin has extended lifespan in mice and improved immune function (Harrison et al., 2009).
  • Metformin users show reduced incidence of age-related diseases and improved survival in observational studies.
  • JAK inhibitors reduce frailty and inflammation in aged mice.

    • ---

    Practical Protocols and Dosing Information

    Senolytic Protocols (Informational Purposes Only)

  • Dasatinib + Quercetin (D+Q):

    • - Dasatinib: 100 mg once daily

    - Querc